LLY · News · 20260807N
Product / Drug Pipeline Progress - retatrutide
ELI LILLY & Co · 2026-08-07 · Importance 44 · Surprise 60 · In source text
Lilly began offering limited expanded access to investigational retatrutide before potential U.S. FDA approval. Eligibility is restricted to adults with refractory obesity, at least two serious obesity-related complications, and no ability to enroll in a clinical trial. Retatrutide targets three metabolic hormones and produced average weight loss of 22.6% at the highest weekly dose in trials. Lilly plans to submit the drug for FDA approval in the first quarter of 2027, positioning it as a next-generation competitor to Wegovy and other existing obesity treatments.
Key facts
- Seeking Alpha reported EBGLYSS achieved 131% year-over-year sales growth and secured a label expansion, offering a 6-dose annual maintenance regimen for moderate-to-severe atopic dermatitis. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Seeking Alpha reported EBGLYSS achieved 131% year-over-year sales growth and secured a label expansion, offering a 6-dose annual… |